# Relmada Therapeutics, Inc.: overview RLMD · Nasdaq · CIK 1553643 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rlmd.md) · [Financials](/companies/rlmd/financials.md) · [Filings](/companies/rlmd/filings.md) · [Insiders](/companies/rlmd/insiders.md) Latest reported revenue: [$682](/filings/0001255294-14-000328.md) for Q2 FY2015, three months to 2014-02-28, from the 10-Q filed Apr 15, 2014 (XBRL us-gaap:Revenues, accession 0001255294-14-000328). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.72)](/filings/0001213900-25-109983.md) | not reported | [(0.58)](/filings/0001213900-26-055059.md) | [(0.30)](/filings/0001213900-26-086151.md) | [(0.30)](/filings/0001213900-25-109983.md) | not reported | [(0.22)](/filings/0001213900-26-055059.md) | [(0.11)](/filings/0001213900-26-086151.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(7.16)](/filings/0001213900-23-022463.md) | [(5.30)](/filings/0001213900-24-024013.md) | [(3.28)](/filings/0001013762-25-003426.md) | [(2.65)](/filings/0001213900-26-031862.md) | [(1.45)](/filings/0001213900-26-031862.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rlmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $77.3m | 11,164,803 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $76.9m | 11,063,862 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $51.4m | 7,426,780 | | Added +6,137,230 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $50.9m | 7,350,000 | | Reduced −1,124,571 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $47.4m | 6,844,305 | | Added +2,000,925 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $44.2m | 6,391,328 | | Added +129,214 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $33.0m | 4,763,158 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $30.9m | 4,460,210 | | Added +1,383,640 | | [Jones Hill Capital LP](/funds/2102314.md) | 2026-06-30 | $25.3m | 3,655,075 | | Added +3,312,323 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $25.1m | 3,631,195 | | Reduced −1,084,669 | ## Recent filings [All 605 filings](/companies/rlmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 08:00 ET | [8-K](/filings/0001213900-26-097851.md) | 8.01 Other events | 0001213900-26-097851 | | 2026-08-06 | 16:40 ET | [8-K](/filings/0001213900-26-086190.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-086190 | | 2026-08-06 | 16:14 ET | [10-Q](/filings/0001213900-26-086151.md) | Quarterly report, period 2026-06-30 | 0001213900-26-086151 | | 2026-07-28 | 08:35 ET | [8-K](/filings/0001213900-26-082007.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-082007 | | 2026-05-28 | 16:59 ET | [8-K](/filings/0001213900-26-062184.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-062184 | | 2026-05-12 | 17:00 ET | [8-K](/filings/0001213900-26-055164.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-055164 | | 2026-05-12 | 16:05 ET | [10-Q](/filings/0001213900-26-055059.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055059 | | 2026-04-17 | 16:30 ET | [DEF 14A](/filings/0001213900-26-045192.md) | Proxy statement, period 2026-05-27 | 0001213900-26-045192 | | 2026-03-20 | 16:52 ET | [8-K](/filings/0001213900-26-032403.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-032403 | | 2026-03-19 | 16:25 ET | [10-K](/filings/0001213900-26-031862.md) | Annual report, period 2025-12-31 | 0001213900-26-031862 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-031862.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1553643 - Tickers: RLMD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.